News

A study from the University of Technology Dresden, in Germany, reported on attitudes toward the adoption of electronic health (eHealth) solutions among clinicians in neurological practices, and their opinions on the those systems’ requirements and  potential benefits in the field of multiple sclerosis (MS). The study, “Designing an…

The U.S. Food and Drug Administration (FDA) will hold a one-day public hearing on four recent draft guidelines regarding the regulation of human cells, tissues, or cellular or tissue-based products (HCT/Ps). Critics of the proposed regulations warn that they curtail the medical use of autologous cell therapy and biologics, and their future potential…

A Colombian study reported finding an increased risk of multiple sclerosis (MS) associated with a particular allele, or gene variant, in a group of patients from the Colombian capital, Bogotá. The study also found a protective allele — HLA-DRB1*14 — that might explain the low rates of MS observed throughout the…

The Tisch MS Research Center of New York (Tisch MSRCNY) recently announced that its stem cell-based therapy as a potential treatment for multiple sclerosis (MS) will move into Phase 2 clinical testing after encouraging results in a Phase 1 trial, and on the advice of  the U.S. Food and Drug…

Recently, Biogen released results from its Phase 2 acute optic neuritis (AON) RENEW trial which tested Anti-LINGO-1. Learn more about this results here. So what is Anti-LINGO-1? According to the MS Society, Anti-LINGO-1 (also known as BIIB033) is a treatment in development by the pharmaceutical company Biogen which is currently…

A team of researchers recently discovered two novel multiple sclerosis (MS)-associated genes that are regulated by vitamin D levels. The study, titled “The multiple sclerosis susceptibility genes TAGAP and IL2RA are regulated by vitamin D in CD4+ T cells,” was published in the advanced online section of …

Dr. Richard Reynolds of Imperial College London spoke of the importance of philanthropy to research during a December 2015 visit from Nigel Furmston, a supporter of multiple sclerosis (MS) research, who came to the Hammersmith Campus to award the scientist and his team £50,000 to continue its work into disease development. Furmston, whose wife Sharon suffers from…

One of the teams participating in the 10th anniversary of the MS Melbourne Cycle, an annual biking challenge to raise money for MS Australia, has built a bicycle that as closely as possible replicates the physical difficulties and discomforts that typify multiple sclerosis (MS). A collaboration between the company Grey Australia, paralympic athlete Carol…

The Multiple Sclerosis Society of Canada recently published a report documenting and summarizing the most important developments in multiple sclerosis (MS) research during 2015. In early 2015, a Society-funded clinical trial was initiated to study the potential abilities of mesenchymal stem cells (MSCs) to treat MS. The MEsenchymal Stem cell therapy…

A new study from The Weizmann Institute of Science, Israel, found that the inflammatory molecule CXCL12 promotes neuronal repair during spontaneous remission in mice with experimental autoimmune encephalomyelitis (EAE), an animal model of human multiple sclerosis (MS). The chemokine CXCL12 was previously thought to be a pro-inflammatory molecule only. But recent findings have shown…

Tiziana Life Sciences, plc, a biotechnology company specializing in drugs to treat immunological and oncological diseases,  recently announced its intent to further develop foralumab, a fully human monoclonal antibody targeting the CD3 receptor. This approach, aiming to modulate the immune T cell response and achieve immunosuppression, is well-validated and has the potential to…

IQuity Labs, which specializes in diagnostic tests for autoimmune and other diseases, recently announced that it has received $2 million in seed funding to support the launch of its test panels, diagnostic tests designed to confirm the presence or absence of disease at the very onset of symptoms. The first to…

A Canadian study showed that child-onset multiple sclerosis (MS) is characterized by increased functional connectivity within the brain, most likely a compensatory effect to preserve function and protect against physical disability. The study, titled “Alterations in Functional and Structural Connectivity in Pediatric-Onset Multiple Sclerosis,“ was published in the journal …

New research evaluating fingolimod’s clinical efficacy, safety, and tolerability in patients with relapsing-remitting multiple sclerosis (RRMS) largely supported its use, finding that the oral drug’s efficacy in a real-world setting was comparable to results observed in Phase 3 clinical studies. The research article, “Efficacy and Safety of Fingolimod in an Unselected…

A new source of stem cells, the mesenchymal stem cells (MSCs) isolated from the human periodontal ligament (hPDLSCs), offers a potential treatment capable of halting multiple sclerosis (MS) progression. The study, “Alternative source of stem cells derived from human periodontal ligament: a new treatment for experimental autoimmune encephalomyelitis,” was published…

In a recent study, a team of researchers argued that, contrary to what has been proposed, subclinical Bordetella pertussis colonization is an important cause of multiple sclerosis (MS). The study, “The potential role of subclinical Bordetella Pertussis colonization in the etiology of multiple sclerosis,” was published in the journal…

The 5th International Symposium on Gait and Balance in MS, held in September 2015, focused entirely on research into balance and its loss in multiple sclerosis (MS). Nearly 100 clinicians, scientists, engineers, and others sharing this research interest gathered to discuss why and how often MS patients fall, and how to…

Ralph H. Benedict, PhD, professor of neurology at the Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo (UB), has been selected by The International Neuropsychological Society (INS) to receive the 2016 INS Mid-Career Award, also called Arthur Benton Award, for his work on…

MedChew Rx, by AXIM Biotechnology, the world’s first patented cannabinoid release chewing gum for pain and spasticity in multiple sclerosis (MS), is moving into clinical testing. If all goes well, the company plans for a global release date of 2017. Medical cannabis is believed to have considerable promise as a therapy for…

A new randomized and controlled trial is recruiting multiple sclerosis (MS) patients to investigate the effect of a mindfulness-based telemedicine intervention program on patients and their caregivers. The clinical study’s protocol was recently published in the journal Trials, titled “A telemedicine meditation intervention for people with multiple sclerosis…

In a new study, researchers found that additives common to processed foods can damage the tight junctions that protect the intestinal mucosa, and which are essential to the intestinal tolerance and immunity balance that works to prevent autoimmune diseases such as multiple sclerosis (MS). The article, titled “Changes in…

Teva Pharmaceutical Industries Ltd. and Active Biotech have discontinued the use of higher doses of the drug laquinimod in two ongoing multiple sclerosis (MS) studies. The decision was based on a recommendation by the Data Monitoring Committee (DMC) that is supervising the clinical trials after cardiovascular events, none of which were fatal,…

A recent study published in the journal PLOS ONE described a new technique with the potential to spot brain changes in multiple sclerosis (MS) before the onset of symptoms. The technique, which measures brain dynamic activity and brain entropy, may lead to the development of diagnostic — and possibly prognostic —…

The Multiple Sclerosis Association of America (MSAA), a national nonprofit organization and leading resource for the multiple sclerosis (MS) community, recently announced that Gina Ross Murdoch has been named the association’s new president and CEO. Ms. Murdoch is now the MSAA’s leader in areas comprising strategic progress, programmatic growth, and business development strategies.

Researchers found that a group of untreated patients with multiple sclerosis (MS) and patients with chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) carry a specific group of hyperactivated immune cells, the inflammatory CD8+ T cells, suggesting a potential common mechanism contributing to disease pathogenesis. The study, “A Preliminary Comparative…

Gail Pickens-Barger is a doTERRA Elite Wellness Advocate who has been helping students to improve their fitness for 15 years. The yoga instructor is now also dedicated to serving the fitness goals of a particular population — patients with multiple sclerosis (MS). MS is a demyelinating disease in which the insulating layer (called myelin) that…

In a special feature published in the journal American Health & Drug Benefits, authors Stanton R. Mehr, President of SM Health Communications, and Marj P. Zimmerman, President of RxDirections, discuss the many unmet medical needs multiple sclerosis (MS) patients still face in dealing with the…

Results from a small pilot study indicated that high-dose vitamin D supplementation is safe and tolerable in patients with multiple sclerosis (MS), and that it can reduce the presence of autoimmunity-causing immune T cells. Patients are now being recruited for a larger clinical trial. The study, entitled “Safety and immunologic…

A new study investigated the influence of sleep disturbance, fatigue and disability on the quality of life (QOL) in multiple sclerosis (MS) patients. Health-related QOL measurements are important tools for assessing the impact of a disease on self-reported physical, mental, emotional, and social functioning. Most studies show that QOL is not related to…

Novoron Bioscience, Inc., a biotech company focused on developing therapies for disorders of the central nervous system, recently announced that it has received a $680,000 National Institutes of Health (NIH) grant to assess the potential of a new therapeutic approach to induce remyelination in multiple sclerosis (MS). MS is…